Display options
Cite
Benjamin F, Deutsch S, Saperstein H, et al. Prevalence of and markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease. Fertil Steril. 1986;46(2):215-21doi: 10.1016/s0015-0282(16)49514-2.
Benjamin, F., Deutsch, S., Saperstein, H., & Seltzer, V. L. (1986). Prevalence of and markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease. Fertility and sterility, 46(2), 215-21. https://doi.org/10.1016/s0015-0282(16)49514-2
Benjamin, F, et al. "Prevalence of and markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease." Fertility and sterility vol. 46,2 (1986): 215-21. doi: https://doi.org/10.1016/s0015-0282(16)49514-2
Benjamin F, Deutsch S, Saperstein H, Seltzer VL. Prevalence of and markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease. Fertil Steril. 1986 Aug;46(2):215-21. doi: 10.1016/s0015-0282(16)49514-2. PMID: 3015693.
Copy Download .nbib Format: NLM
Share it on
Full text links
Elsevier Science

Fertil Steril. 1986 Aug;46(2):215-21. doi: 10.1016/s0015-0282(16)49514-2.

Prevalence of and markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease.

Fertility and sterility

F Benjamin, S Deutsch, H Saperstein, V L Seltzer

PMID: 3015693 DOI: 10.1016/s0015-0282(16)49514-2

Abstract

To determine the prevalence of the attenuated form of congenital adrenal hyperplasia (CAH) and hyperprolactinemia (HPPN) relative to polycystic ovarian disease (PCOD), 100 consecutive women presenting with the classic clinical features of PCOD were evaluated by basal hormonal profiles and subsequent adrenocorticotropic hormone (ACTH) stimulation tests. The study also sought biochemical markers for CAH other than ACTH stimulation. The prevalences were found to be as follows: PCOD, 65%; PCOD with HPPN, 9%; HPPN, 3%, end-organ hypersensitivity (EOH), 4%; homozygotic CAH, 4%; and heterozygotic CAH, 15%. Other than the differential response to ACTH, the only other biochemical markers observed for homozygotic CAH were significantly higher basal levels of testosterone (T) and 17 alpha-hydroxyprogesterone (17-OHP). Luteinizing hormone/follicle-stimulating hormone ratio, androstenedione, and dehydroepiandrosterone sulfate all showed no significant differences between homozygotic CAH, heterozygotic CAH, HPPN, PCOD, and EOH. This study establishes the relative prevalences of the syndromes commonly mimicking PCOD. We also conclude that the observed low incidence of CAH does not justify routine ACTH testing on all patients presenting with features of PCOD--however, our data suggest that patients with basal serum levels of T and 17-OHP greater than 50% above the upper limit of normal should undergo this dynamic test, especially if there are also certain clinical features suggestive of CAH.

Similar articles

Show all 8 similar articles

Substances

MeSH terms

Publication Types

LinkOut - more resources